|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
|
31655978 |
2020 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer.
|
30717896 |
2019 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
PosttranslationalModification |
BEFREE |
We have characterized TERT promoter methylation, transcription factor binding, and TERT expression levels in five differentiated thyroid cancer (DTC) cell lines and six normal thyroid tissue samples by targeted bisulfite sequencing, ChIP-qPCR, and qRT-PCR.
|
30664813 |
2019 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker |
BEFREE |
Patients referred for radioiodine treatment after thyroidectomy for intermediate- to high-risk differentiated thyroid carcinoma were included in a prospective observational study and tested for TERT promoter, BRAF, and RAS mutations of their primary tumours.
|
30648628 |
2019 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker |
BEFREE |
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
|
28323925 |
2017 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
|
27493271 |
2017 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high-risk patients with DTC.Cancer 2016;122:1370-1379.© 2016 American Cancer Society.
|
26969876 |
2016 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the presence of TERT promoter mutations is independently associated with increased mortality in patients with differentiated thyroid cancer.
|
27528624 |
2016 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Recently, the introduction of next-generation sequencing techniques led to the identification of TERT promoter and TP53 mutations in DTC.
|
27578827 |
2016 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
The role of telomerase reverse transcriptase (TERT) promoter mutations in differentiated thyroid cancer has been well established.
|
27184112 |
2016 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Frequent coexistent TERT promoter and BRAF or RAS mutations in metastatic DTC also suggests its important role in the progression of DTC.
|
26971368 |
2016 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
The aggressive role of TERT promoter mutations has been well established in differentiated thyroid cancer but has not been established in anaplastic thyroid cancer (ATC).
|
25584719 |
2015 |
|
LOC110806263
|
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |